Australia is facing a growing crisis with novel benzodiazepines flooding unregulated markets nationwide. Between 2020 and 2025, detections of these dangerous substances surged dramatically across the country. Manufactured illegally and never approved for medical use, these drugs now pose significant health risks to communities everywhere. A comprehensive narrative review of Australian peer-reviewed literature and public drug alerts reveals just how alarming the trend has become.

What Are Novel Benzodiazepines Australia Deals With?

Novel benzodiazepines are unregulated drug analogues that no authority has approved for medical use. Unlike prescription benzodiazepines such as diazepam (Valium) or alprazolam, manufacturers produce these substances illegally, often marketing them as counterfeit pharmaceuticals.

Chemically, NBZs share a similar composition to prescribed medications and target the same brain receptors to produce sedative and anxiety-reducing effects. However, they tend to be significantly more potent than their pharmaceutical counterparts, and their effects typically last longer as well.

The most commonly detected novel benzodiazepines in Australia include etizolam, clonazolam, clobromazolam, bromazolam, flualprazolam, and flubromazolam. In most cases, users ingest these substances orally, as sellers market them as counterfeit tablets designed to mimic brand-name medicines. Beyond tablets, however, they also circulate as powders, liquids, or gummies.

NBZs Australia: Alarming Statistics

Recent Australian data paints a troubling picture. Between January 2020 and June 2025, authorities issued 23 public drug warnings nationwide. Notably, nearly half of these alerts (11 out of 23) came in just the first six months of 2025, indicating a rapidly escalating situation.

Emergency departments now identify NBZs as the most common new psychoactive substances in toxicology monitoring programmes. Consequently, Victoria’s Emerging Drugs Network recorded 140 deaths between 2015 and 2023 involving novel benzodiazepines. The first death occurred in 2015, and fatalities remained rare until 2019. From that point, however, annual deaths increased dramatically, peaking in 2022 with 40 cases.

The victims are predominantly young adult males, with a median age of 26.5 years. Furthermore, in nearly every fatal case, toxicologists detected at least one additional central nervous system depressant alongside the NBZ. This pattern highlights the extreme dangers of combining these substances.

The Counterfeit Crisis: Novel Benzodiazepines in Australia

NBZs present themselves deceptively. Manufacturers design counterfeit tablets to mimic brand-name medicines, using convincing packaging and appearance to fool consumers. In Australia, the most commonly identified falsified presentations are products branded as “Xanax” and “Mylan”, and neither brand is legitimately available in the Australian market.

Forensic analysis of seized samples reveals the full extent of this deception. Researchers analysed 809 falsified alprazolam tablets in New South Wales, and only 70 samples (8.7%) actually contained alprazolam. Instead, the most frequently detected substances were novel benzodiazepines: etizolam (28%), clonazolam (28%), and bromazolam (22%).

In turn, the variability in these counterfeit products is equally alarming. Dosage and strength vary significantly between products and, in some cases, even within a single batch. A single tablet can contain multiple NBZ compounds simultaneously. Toxicological analyses of emergency department patients identified five separate NBZs within blood samples from just six individuals, all of whom believed they were taking alprazolam.

Health Risks of NBZs Australia

Novel benzodiazepines pose substantial health risks, largely due to their unpredictable nature. Adverse effects include intense sedation, amnesia, and respiratory depression. Compared to pharmaceutical benzodiazepines, NBZs consequently carry greater risks, including acute toxicity and severe withdrawal.

Clinical case studies from Australian emergency departments reinforce these concerns. Patients exposed to NBZs experience prolonged periods of sedation, with some remaining sedated beyond 24 hours. In serious cases, this extended sedation can progress to coma and respiratory depression. No patients presenting to emergency departments reported deliberately using novel benzodiazepines by name. This strongly suggests that people obtaining benzodiazepines from unregulated markets often have no idea what they are actually consuming. Our understanding of NBZ pharmacodynamic and pharmacokinetic profiles is still developing. Nevertheless, available data shows these drugs act on similar brain receptors to prescribed benzodiazepines, though certain NBZs such as clonazolam and bromazolam possess particularly strong sedative and amnestic properties, even at low doses.

Novel Benzodiazepines Australia and Polysubstance Dangers

Polysubstance use presents a particularly concerning pattern. Research shows toxicologists detected other central nervous system depressants in 95–100% of NBZ-related deaths. The danger multiplies significantly when people combine benzodiazepines with other depressants such as alcohol, opioids, or GHB, as synergistic effects exacerbate both sedation and respiratory compromise.

Some users report taking benzodiazepines specifically to manage the effects of other substances. Studies found 42% used these drugs to sleep or come down after stimulants, while another 40% reported using them for relaxation. Additionally, 35% turned to them to alleviate anxiety, and 31% used them for insomnia support. This layered pattern of use creates compounding layers of risk that are difficult to predict or manage.

Detection and Treatment Challenges for NBZs Australia

Healthcare providers face unique challenges when managing NBZ-related health issues. Many novel benzodiazepines do not cross-react with standard urine drug screening immunoassays. In contrast, more sophisticated tests like liquid chromatography-mass spectrometry can identify specific NBZs; however, these tests are expensive, slow, and not widely available. As a result, people seeking treatment for substance use may have their NBZ consumption completely overlooked.

The poorly defined pharmacological profiles of NBZs create further difficulties. Clinicians struggle to predict the onset, intensity, and duration of withdrawal symptoms, which complicates clinical decision-making considerably. Doctors must determine whether someone has used a short-acting or long-acting NBZ, since short-acting variants prompt rapid withdrawal while long-acting variants delay symptom onset.

Reliable potency conversions between NBZs and prescribed benzodiazepines do not currently exist, making it difficult to determine an appropriate treatment schedule. International reports show that some treatment providers refuse to provide care altogether, as they lack familiarity with appropriate management strategies. This potentially leaves vulnerable individuals without support during critical periods.

Prevention Through Education

Given these risks, prevention through education becomes paramount. Public awareness campaigns must emphasise several key messages about novel benzodiazepines in Australia.

Understanding the Risk: Specifically, any benzodiazepine sourced from anywhere other than a registered pharmacist could be counterfeit and may contain NBZs. Products branded as “Xanax” are particularly concerning, as this brand is not legitimately available in Australia.

Recognising Unpredictability: Even visually similar counterfeit tablets can contain vastly different substances and dosages. The greatest dose variation observed was for etizolam, which ranged from 0.7 to 8.3mg per tablet in identical-looking products.

Appreciating Delayed Effects: The effects of certain benzodiazepines or NBZs can take up to two hours to appear, and some effects last for over 24 hours. This delayed onset increases the risk of taking additional doses before the initial dose takes full effect.

Understanding Tolerance and Dependence: Novel benzodiazepines pose a higher risk of dependence than prescription benzodiazepines. They often produce stronger effects and can more rapidly lead to tolerance. Prolonged use consequently increases both tolerance and the risk of dependence, and severe, potentially fatal, withdrawal symptoms can occur when people discontinue use abruptly.

The Regulatory Context

Changes in prescription regulations partially explain the emergence of novel benzodiazepines in Australia. Following opioids, benzodiazepines are the second most common drug class associated with overdose. In 2023 alone, they contributed to 694 (39%) of such deaths.

The rate of benzodiazepine prescribing has declined over the last decade, driven largely by regulatory changes. Authorities up-scheduled alprazolam from a Schedule 4 (prescription medication) to a Schedule 8 (controlled drug) in 2014, with further restrictions introduced in 2017. Overall, these regulations led to a reduction in alprazolam use among certain populations. On the other hand, some researchers speculate that increasing regulation may have inadvertently pushed some individuals toward unregulated markets in search of alternatives.

The 2022–2023 National Drug Strategy Household Survey provides revealing data on this shift. It found 1.6% of Australians aged 14 and over reported non-medical use of tranquillisers or sleeping pills within the last 12 months, though this is likely a conservative estimate, as household surveys typically see under-reporting of drug use. Among people who regularly use drugs, the prevalence is substantially higher: 25% of people who regularly inject drugs reported using non-prescribed benzodiazepines, and similarly, 28% of those who regularly use ecstasy reported such use within the previous six months.

Knowledge Gaps Regarding Novel Benzodiazepines Australia

Despite growing concerns, significant knowledge gaps remain. Most research has focused on analytical detection rather than exploring the experiences and motivations of the people who actually encounter these substances. No recent Australian qualitative studies have examined people who source benzodiazepines from unregulated markets, which limits our evidence on motivations, contexts, and experiences considerably.

Future research must therefore prioritise several areas, including investigations into the pharmacology of NBZs, the risks tied to counterfeit products, and the knowledge levels of potential consumers. Understanding why people seek benzodiazepines from unregulated markets is particularly essential, and common reasons include untreated anxiety, insomnia, or managing the effects of other substances. This understanding will ultimately help develop more effective prevention strategies.

A Growing Public Health Concern

Novel benzodiazepines represent a significant and growing public health concern in Australia. The increase in drug alerts tells this story clearly: fewer than three alerts per year came between 2020 and 2023, yet this jumped to 11 alerts in just the first half of 2025. This sharp escalation demonstrates the rapidly evolving nature of the threat.

NBZs generally produce effects similar to pharmaceutical benzodiazepines; however, they are more potent, carry unknown or inconsistent dosages, and their pharmacological properties remain poorly understood. At the same time, the circulation of convincing counterfeit products creates an additional layer of danger, as individuals may believe they are taking known quantities of regulated medications when, in reality, they are exposed to unpredictable and potentially dangerous substances.

Indeed, Australian coronial, toxicological, forensic, and emergency department data sources have consistently detected novel benzodiazepines from 2020 to 2025. This confirms the situation is not a transient phenomenon but rather an established and escalating pattern. The predominance of young adult males among fatalities is concerning, and the near-universal presence of other central nervous system depressants in fatal cases highlights both specific at-risk populations and dangerous consumption patterns that demand urgent attention.

Conclusion

Education remains the cornerstone of prevention. People need to understand what novel benzodiazepines are, recognise the risks of counterfeit medications, and appreciate the dangers of polysubstance use. Moreover, knowing the signs of dependence is equally important. In essence, with this knowledge, individuals can make more informed decisions about their health and safety.

Those struggling with anxiety, insomnia, or other conditions should consult qualified healthcare professionals, as this remains the safest pathway to appropriate treatment. For those concerned about substance use, numerous support services exist across Australia that can help both individuals and their loved ones navigate these challenges.

The landscape of unregulated drugs continues to evolve rapidly, as this research clearly demonstrates. Ongoing surveillance, timely public alerts, continued research, and comprehensive education programmes will all play vital roles in addressing this emerging public health challenge.

Source: onlinelibrary